Why Gilead Sciences Stock Is Rising After Hours

Gilead Sciences Inc GILD shares are trading higher in Thursday's after-hours session after the company reported better-than-expected financial results and raised its full-year outlook.

Gilead said third-quarter revenue decreased 5% year-over-year to $7.04 billion, which beat average analyst estimates of $6.12 billion, according to Benzinga Pro. The company reported quarterly earnings of $1.90 per share, which beat average estimates of $1.48 per share. 

Product sales excluding Veklury increased 11% year-over-year to $6.1 billion. Biktarvy sales increased 22% year-over-year to $2.8 billion, and oncology sales increased 79% year-over-year to $578 million.

"Overall, we are seeing terrific progress from a commercial and clinical perspective and look forward to building on this momentum," said Daniel O'Day, chairman, and CEO of Gilead.

Gilead increased its full-year product sales outlook to a range of $25.9 billion to $26.2 billion. The company also raised full-year earnings guidance from a range of $2.90 to $3.30 per share to a range of $3.35 to $3.55 per share. 

See Also: Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

GILD Price Action: Gilead has a 52-week high of $73.39 and a 52-week low of $57.16.

The stock was up 3.7% at $72.80 after-hours at the time of publication.

Photo: Konstantin Kolosov from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsAfter-Hours CenterMoversTrading IdeasGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!